Corinne Le Goff: Right, good morning James. So as I mentioned, this trial is under the sponsorship of the Break Through Cancer Foundation. We’re supposed to have four centers enrolling patients in this clinical trial. The first center in Anderson is up and running. They have not enrolled any patients yet, but they are definitely up and running. And we are expecting the other centers to join the study in Q3 – I mean maybe September, October time frame this year. For Phase I/II, which means that the first phase of this trial is really to evaluate the dose that we need to administer to patients in combination with AVASTIN and then the Phase II will come after. So it’s a bit difficult at the moment to give you exactly when we can get some first data, but certainly, in the course of 2024, we have more certainty as the new the new centers involve. Khursheed, do you want to add anything to what I said? I know you’ve been talking with the investors here as well.
Khursheed Anwer: Sure. No, you’re right. I mean the infill part as Corinne said, is to demonstrate safety in combination with the AVASTIN and the chemo. And once the four sites that we have targeted come on board, the Phase I portion should not take much. I don’t want to put a date or time, but I think it’s just starting now. So Phase I sources should not take a longer time before we get into Phase II. So September, October – October time we anticipate all sites to be onboard. It’s only a matter of, perhaps I would say, three to four months after that.
James Molloy : Okay, great, thank you. And is there a – I have on sort of my model expectations for maybe another combo at some point with OPDIVO. Is that something that you guys are still looking at for Epithelial Ovarian Cancer?
Corinne Le Goff: Hi James. Yes, so I think I would say, in theory I believe that there is a lot of value in testing IL-12 accommodation, because mechanistically that makes a lot of sense to add an IL-12 with a checkpoint inhibitor for instance, right, because it’s all about motivating the macro environment. So we might think about this. I mean, we do one thing at a time right. The reason why we engaged in a combination trial with AVASTIN now is because we have very compelling synergistic data in a preclinical model in mice. But it’s not out of the question to think that a combination with a checkpoint inhibitor could be an interesting trial as well.
James Molloy : Absolutely. So I know you have limited resources as everyone does. Actually at that point has there been any discussion to the effect of any larger pharma partners that are coming in to partner to help with the R&D?
Corinne Le Goff: On the IL-12 program, you’re asking specifically?
James Molloy : Really IL-12 or really across the board, looking at the technology stand, that’s pretty good. We want to get in on that?
Corinne Le Goff: So yes, I mean collaboration and partnership will be key to our operating model. So we’ll – certainly we’ll seek partnerships. That’s why we’re also eager to get into a Phase I program with our vaccine modality, so that we can get to this proof of principle in humans, and then I’m sure that that will open doors for collaborations after that.
James Molloy : Absolutely. Thank you for taking the questions.
Corinne Le Goff: Thank you.
Operator: This concludes our question-and-answer session. I would like now to turn the conference back over to Dr. Corinne Le Goff for any closing remarks.